The recent identification of reliable adult stem cell markers in the intestine has driven major advances in our understanding of stem cell roles in both normal tissue homeostasis and cancer. A principal route to colon cancer initiation is aberrant activation of Wnt signalling activity in long-lived adult stem cells at the crypt base. Tumour-resident stem cell populations within the resulting adenomas are considered likely targets for accumulation of additional mutations, driving a stepwise transition towards invasive carcinoma. These purported cancer stem cell populations have received widespread interest as potential therapeutic targets, fuelling efforts to identify specific biomarkers that facilitate their isolation and/or the development of tailored drugs. Here we review recent advances in (cancer) stem cell biology and highlight the obstacles to translation of this knowledge into therapeutic applications in the clinic.
Share this Article
Related Content In Gastrointestinal Oncology
Treatment Options in BRAF-mutant Metastatic Colorectal Cancer
touchREVIEWS in Oncology & Haematology. 2022;18(2):103-6 DOI: https://doi.org/10.17925/OHR.2022.18.2.103
Until recently, treatment options for metastatic colorectal cancer (CRC) have been limited to a cytotoxic chemotherapy with or without an anti-epithelial growth-factor receptor (EGFR) monoclonal antibody, namely cetuximab and panitumumab, or an anti-angiogenic agent such as bevacizumab, aflibercept or ramucirumab. For subsequent lines of treatment, the tyrosine kinase inhibitor regorafenib is an important part of […]
Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers
touchREVIEWS in Oncology & Haematology. 2022;18(1):16–25 DOI: https://doi.org/10.17925/OHR.2022.18.1.16
Gastro-oesophageal cancers (GEC), which include both gastric (GC) and oesophageal cancers (EC), are among the most common cancers globally.1 In the USA, the American Cancer Society estimated 20,640 new diagnoses of EC and 26,380 new diagnoses of GC, each contributing to 16,410 and 11,090 deaths, respectively, in 2022 alone.2,3 GEC is divided based on the histology of squamous […]
Cholangiocarcinoma: The Present and Future of Targeted Therapies
touchREVIEWS in Oncology & Haematology. 2022;18(1):9–15 DOI: https://doi.org/10.17925/OHR.2022.18.1.9
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1 CCAs tend to metastasize and have early lymph node involvement. As a result, only a small proportion of patients are considered for surgical management, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!